IGNITE DMD Phase I/II Clinical Trial Community Letter

Solid Biosciences provided an update on their programs this week. Notably, their microdystrophin Phase 1/2 trial continues to dose participants, and they are on track to report dystrophin levels and functional outcomes data in the first half of 2022.  They also continue to advance their next-generation gene therapy program in Duchenne. 

Read the Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and 2022 Priorities here: https://www.solidbio.com/about/media/news/letter-to-the-duchenne-community-ignite-dmd-phase-i-ii-clinical-trial-and-2022-priorities